Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Shanghai Cell Therapy Group Co. Ltd. is a Chinese company located in Shanghai that operates as a cell therapy company. The firm was founded in 2013 by Jie Wei Li.\nThe company says this about itself: Founded in 2013, Shanghai Cell Therapeutics Group Co., Ltd is located at the Shanghai Municipal Engineering and Technology Research Center, which was established by the Shanghai Science and Technology Commission. With a mission of \"changing the length and abundance of life with cell therapy\", SHCell has created a closed-loop industrial chain and an integrated platform for cell treatment and cell therapy. It comprises cell storage, cell drug research and cell clinical transformation with cell therapy as its core business.

Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.

Allogene Therapeutics is a clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Part of Amgen, Inc., Amgen Research (Munich) GmbH is a German company located in Munich. The firm produces copper and metal powders. Robert Saller and Peter Kufer are the current co-CEOs of the firm. On June 13, 2002 ECKA Granulate GmbH & Co. KG acquired Amgen Research (Munich) GmbH from Aurubis AG.

Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd. is a company headquartered in Songjiang, China. The firm provides cancer treatment services.

Gracell Biotechnologies (Shanghai) Co., Ltd., part of Gracell Biotechnologies, Inc., is a company headquartered in Shanghai, China, that operates a clinical-stage biopharmaceutical company which discovers and develops cellular therapeutics for the patients suffering with cancer. It was founded in 2017 by Wei Cao, who has been the CEO since the inception date.\nThe company says this about itself: Gracell Biotechnologies Co., Ltd. (\"Gracell\") is a clinical-stage biotechnology company, committed to developing highly efficacious and affordable cell and gene therapies for the treatment of cancer. Gracell is dedicated to resolving the remaining challenges in CAR-T, such as high production costs, lengthy manufacturing process, lack of off-the-shelf products, and inefficacy against solid tumors. Led by a group of world-class scientists, Gracell is advancing FasTCAR™ (overnight production and younger cell phenotype), TruUCAR™ (off-the-shelf), DualCAR and EnhancedCAR T cell therapies for leukemia, lymphoma, myeloma, and solid tumors.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Lentigen Corporation, a biotechnology company, engages in the development and commercialization of gene delivery technologies for human disease. It provides lentiviral vector technology for a range of therapeutic, vaccine, and research applications in biotechnology and medicine. The company offers LG690, a cell therapy for treatment of graft vs hot diseases; LG768, a cancer vaccine for the treatment of leukemia; stem cell therapy to prevent and treat medical disorders; LG631, a treatment that makes chemotheraphy for brain cancer less toxic; LG889, a steam cell therapy for hemophilia; LG611, an exact strain matched influenza vaccine for pandemic flu; LG811, an exact strain matched influenza vaccine for seasonal flu; LG747, a biosimilar erytho poieitin; and LG888, a novel factor VIII protein therapy for Hemophilia A. Lentigen Corporation was founded in 2004 and is headquartered in Gaithersburg, Maryland.

Cell Design Labs is a biotherapeutics company pioneering breakthrough science to develop disruptive cell-based therapies for cancer and other devastating diseases. Cell Design Labs leverages the power of the body’s immune system to develop smart, living therapies with the capability to treat our most challenging diseases with unprecedented power, precision, safety and durability

Cartesian Therapeutics, Inc. manufacturers biological products. The company was founded by Murat Kalayoglu and Michael Singer in 2016 and is headquartered in Gaithersburg, MD.

Shanghai Yihao Biotechnology Co., Ltd., established on 2017-12-20, Business scope includes general items:engaged in biotechnology(genetically modified organism,Except human stem cell genetic diagnosis),Medical Technology,Technology development in the field of chemical science and technology,technical consulting,technology transfer,Technical Services,Edible produce,Chemical raw materials and products(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals);Experimental analysis instrument sales;Sales of hygiene products and single-use medical products;Optical Instrument Sales;Instrumentation,Sales of glass products;Biochemical product technology research and development;Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals);Chemical product sales(No licensed chemical products);Specialty Chemicals Sales(Free of Hazardous Chemicals);Sales of Class I Medical Devices;Sales of Class II Medical Devices;Information Consulting Service(Not including licensing information consulting services).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license) licensed items:Class III medical device business;Import and export;Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Hrain Biotechnology Co., Ltd. engages in the research and development, and production of immune cell therapy products. It offers chimeric antigen receptor (CAR) T-cell therapy, chimeric antigen receptor-transduced natural killer (CAR-NK) cell therapy, dash chimeric antigen receptor (CAR) T-cell therapy. The company was founded by Pin Wang on July 20, 2015 and is headquartered in Shanghai, China.

Eureka Therapeutics, Inc. develops therapeutic monoclonal antibodies for cancer indication and treatment. It focuses on the discovery of fully-human antibody drugs for the treatment of cancer and utilizing its antibody drug discovery and engineering technologies, and advancing therapies for targeting previously inaccessible cancer antigens. The company was founded by Cheng Liu in 2006 and is headquartered in Emeryville, CA.

ounded in 2014, Wuhan Bio-Raid Biotechnology Co., Ltd. is a high-tech enterprise focusing on CAR-T cell immunotherapy. Bio-Raid has developed a number of patented technologies, and established a broad pipeline of CAR-T product candidates covering blood and solid tumors and HIV areas of significant unmet medical need.

Atara Biotherapeutics, Inc. (@Atarabio) is an off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory, and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California. For additional information about the company, please visit atarabio.com.

Poseida Therapeutics is a clinical-stage biopharmaceutical company utilizing genome engineering capabilities to develop targeted therapeutics for patients with high unmet medical needs. The company develops a pipeline of autologous and allogeneic chimeric antigen receptor T cell or CAR-T, product candidates focusing on the treatment of hematological malignancies and solid tumors. Poseida Therapeutics was founded in 2014 and is headquartered in San Diego, California.

Suzhou Proda Biotechnology Co., Ltd., established on 2012-12-22, Business scope includes biomedicine,Health products,food,cosmetic,medical instruments,Non-hazardous chemical products,Research and development of sewage treatment technology,Technical cooperation,technical consulting,technology transfer;Sales:Non-hazardous chemical products,Class I medical device,cosmetic.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)